MME and Alzheimer disease: Another study demonstrated in the AD mouse model that the use of RGFP-966 (a brain-penetrant and selective HDAC3 inhibitor) increased plasma levels of NEP, decreased Aβ at brain and peripheral levels, and improved spatial learning and memory (Janczura et al., 2018).